The system can perform automated phenotypic antimicrobial susceptibility testing and minimum inhibitory concentration analysis in approximately 24 hours.

Mediford will provide access to C2N's Biopharma Clinical Research Services, which offer mass spec-based assays for analytes linked to human neurological diseases.

Mediford will provide access to C2N's Biopharma Clinical Research Services, which offers mass spec-based assays for analytes linked to human neurological diseases.

The cases could overturn a legal principle known as the "Chevron doctrine" under which courts have typically deferred to ...

In one case, the owners of an independent laboratory have been charged in a $36 million COVID-19 testing fraud scheme.

Though COVID test sales were behind the decline in revenues, the firm expects there won’t be any further material impact on its sales from such tests.

The money, which includes an equity investment, will be used to advance the company's breath-based diagnostic technology for respiratory disease.

Among the charges against the owners of Innovative Genomics are allegations that they submitted healthcare benefit claims for unnecessary and non-reimbursable COVID-19 testing.

With a leaner team and budget, the program aims to accelerate novel diagnostics that fill unmet needs while also propagating its model throughout other NIH divisions.

The firm's revenues for Q1 were $3.18 billion, up from $3.04 billion in the same quarter last year and above the consensus Wall Street estimate of $3.12 billion.

The cases could overturn a legal principle known as the "Chevron doctrine" under which courts have typically deferred to agency interpretation of ambiguous statutes.

The FDA's new quality system rules will be aligned with the ISO 13485 standard starting in early 2026, raising alarm bells, ...